Hemagen Diagnostics Revenue vs. Current Valuation
| HMGNDelisted Stock | USD 0.0001 0.00 0.00% |
For Hemagen Diagnostics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Hemagen Diagnostics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Hemagen Diagnostics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Hemagen Diagnostics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Hemagen Diagnostics over time as well as its relative position and ranking within its peers.
Hemagen |
Hemagen Diagnostics Current Valuation vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Hemagen Diagnostics's current stock value. Our valuation model uses many indicators to compare Hemagen Diagnostics value to that of its competitors to determine the firm's financial worth. Hemagen Diagnostics is rated # 3 in revenue category among its peers. It is rated below average in current valuation category among its peers reporting about 0.11 of Current Valuation per Revenue. The ratio of Revenue to Current Valuation for Hemagen Diagnostics is roughly 9.15 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Hemagen Diagnostics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Hemagen Diagnostics' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Hemagen Revenue vs. Competition
Hemagen Diagnostics is rated # 3 in revenue category among its peers. Market size based on revenue of Health Care industry is currently estimated at about 493.18 Million. Hemagen Diagnostics maintains roughly 4.04 Million in revenue contributing less than 1% to equities under Health Care industry.
Hemagen Current Valuation vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Hemagen Diagnostics |
| = | 4.04 M |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Hemagen Diagnostics |
| = | 441.76 K |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Hemagen Current Valuation vs Competition
Hemagen Diagnostics is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is currently estimated at about 19.8 Billion. Hemagen Diagnostics adds roughly 441,758 in current valuation claiming only tiny portion of equities under Health Care industry.
Hemagen Diagnostics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Hemagen Diagnostics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Hemagen Diagnostics will eventually generate negative long term returns. The profitability progress is the general direction of Hemagen Diagnostics' change in net profit over the period of time. It can combine multiple indicators of Hemagen Diagnostics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Hemagen Diagnostics, Inc., a biotechnology company, provides human and veterinary clinical diagnostic solutions worldwide. The company was founded in 1985 and is based in Columbia, Maryland. Hemagen Diagnostics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 15 people.
Hemagen Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Hemagen Diagnostics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Hemagen Diagnostics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Hemagen Diagnostics' important profitability drivers and their relationship over time.
Use Hemagen Diagnostics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Hemagen Diagnostics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Hemagen Diagnostics will appreciate offsetting losses from the drop in the long position's value.Hemagen Diagnostics Pair Trading
Hemagen Diagnostics Pair Trading Analysis
The ability to find closely correlated positions to Hemagen Diagnostics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Hemagen Diagnostics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Hemagen Diagnostics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Hemagen Diagnostics to buy it.
The correlation of Hemagen Diagnostics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Hemagen Diagnostics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Hemagen Diagnostics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Hemagen Diagnostics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Hemagen Diagnostics position
In addition to having Hemagen Diagnostics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Insurance Thematic Idea Now
Insurance
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Insurance theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Insurance Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Other Consideration for investing in Hemagen Pink Sheet
If you are still planning to invest in Hemagen Diagnostics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Hemagen Diagnostics' history and understand the potential risks before investing.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |